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Key questions
What is already known about this subject?
 ► The Ross operation has recently shown favourable 
outcomes compared with other aortic valve replace-
ment options in young adults.
What does this study add?
 ► In this study we have found that the Ross operation 
has better outcomes, such as mortality, freedom 
from reintervention or freedom from embolic events, 
and is more economically efficient in the long term 
compared with conventional aortic valve replace-
ment in the young.
 ► Additionally, we propose that a comparative clinical 
trial with a budget of £2 million would be warranted 
and cost-effective.
How might this impact on clinical practice?
 ► Young patients who undergo conventional aortic 
valve replacement, such as with mechanical or bi-
ological prosthesis, face either lifelong anticoagula-
tion and embolic risks, or rapid valve degeneration 
and reinterventions, respectively.
 ► The Ross procedure is re-emerging as a better op-
tion in this age group.
 ► Lower overall costs reflect these better outcomes, 
but available data are only retrospective.
 ► A randomised clinical trial, shown in this study to be 
economically efficient, is planned to directly com-
pare aortic valve replacement options in non-elderly 
patients.
AbstrAct
Objectives In young and middle-aged adults, there are 
three current options for aortic valve replacement (AVR), 
namely mechanical AVR (mechAVR), tissue AVR (biological 
AVR) and the Ross operation, with no clear guidance on the 
best option. We aim to compare the clinical effectiveness 
and cost-effectiveness of the Ross procedure with 
conventional AVR in young and middle-aged adults.
Methods This is a systematic literature review and meta-
analysis of AVR options. Markov multistate model was 
adopted to compare cost-effectiveness. Lifetime costs, 
quality-adjusted life years (QALYs), net monetary benefit 
(NMB), population expected value of perfect information 
(EVPI) and expected value of partial perfect information were 
estimated.
Results We identified 48 cohorts with a total number of 
12 975 patients (mean age 44.5 years, mean follow-up 
7.1 years). Mortality, bleeding and thromboembolic events 
over the follow-up period were lowest after the Ross 
operation, compared with mechAVR and biological AVR 
(p<0.001). Aortic reoperation rates were lower after Ross 
compared with biological AVR, but slightly higher when 
compared with mechAVR (p<0.001). At a willingness-
to-pay threshold of £20effective. At a willingness-to-pay 
threshold of £20, 000 per QALY000 per QALY, the Ross 
procedure is more cost-effective compared the Ross 
procedure is more cost-effective compared withwith 
conventional AVR, with a lifetime incremental NMB of £60 
conventional AVR, with a lifetime incremental NMB of £60 
952 (952 (££3030 236236 to to ££7979 464). Incremental 
costs were £12464). Incremental costs were £12 323 (323 
(££61086108 to to ££1515 972) and incremental QALYs 
3.66 (1.81972) and incremental QALYs 3.66 (1.81 to to 
4.76). The population EVPI indicates that a trial costing up 
to £2.03 million could be cost 4.76). The population EVPI 
indicates that a trial costing up to £2.03 million could be 
cost--effective.
At a willingness-to-pay threshold of £20 000 per QALY, 
the Ross procedure is more cost-effective compared with 
conventional AVR, with a lifetime incremental NMB of £60 
952 (£30 236 to £79 464). Incremental costs were £12 
323 (£6108 to £15 972) and incremental QALYs 3.66 (1.81 
to 4.76). The population EVPI indicates that a trial costing 
up to £2.03 million could be cost-effective.
Conclusions In young and middle-aged adults with aortic 
valve disease, the Ross procedure may confer greater quality 
of life and be more cost-effective than conventional AVR. A 
high-quality randomised trial could be warranted and cost-
effective.
IntROduCtIOn
The standard treatment for aortic valve 
(AoV) disease is aortic valve replacement 
(AVR) when repair is not possible.1 Options 
include mechanical (mechAVR) and biolog-
ical (biological AVR) prostheses, or conven-
tional AVR (cAVR) and the Ross procedure 
(pulmonary autograft), and rarely homo-
graft valves. Bioprostheses are durable in 
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older patients,2 with the survival advantage of mechAVR 
over biological AVR disappearing around the age of 60.3 
However, decision making in young and middle-aged 
adults is challenging, with a more marked impact of cAVR 
on survival in younger patients,4 and with biological AVR 
and mechAVR being associated with reduced life expec-
tancy.5 Furthermore, there are issues with biological valve 
degeneration and mechanical valve need for anticoagula-
tion, which are more important in young patients.
Critics of the Ross procedure point out that it creates 
a ‘two-valve disease’. However, multiple studies show very 
good early results and better long-term survival, compa-
rable with that of the general population.6–8 The Ross 
procedure affords superior haemodynamics in the auto-
graft9 and typically uses a homograft in the lower pres-
sure pulmonary circulation. Despite better outcomes, 
the Ross procedure is underused, partly due to tech-
nical complexity. However, it can be performed safely in 
congenital centres and hospitals where complex aortic 
root operations are routine.10
Cost-effectiveness analysis compares the costs and 
effects of treatments, usually measured as quality-ad-
justed life years (QALYs), on a monetary scale and thus 
aids reimbursement decision making by healthcare 
payers.11 To date there have been no cost-effectiveness 
analyses evaluating the Ross procedure as an option for 
aortic stenosis (AS) in young and middle-aged adults. 
Previous economic evaluations have compared cAVR and 
transcatheter aortic valve implantation (TAVI) with each 
other and with medical management.12–14 The results 
have been variable with respect to the cost-effectiveness 
of TAVI compared with cAVR in high-risk patients, both 
being cost-effective compared with medical manage-
ment.13–15 Value of information analysis is a method to 
use the outputs of cost-effectiveness analyses to prioritise 
and design research.11 Only one publication, comparing 
TAVI and medical management, has applied value of 
information analysis to AS.16
Using meta-analysis, we compared the clinical effec-
tiveness of the Ross procedure with biological AVR and 
mechAVR for the treatment of young and middle-aged 
adults with AS. We then used these results to inform a 
comprehensive cost-effectiveness comparison of these 
procedures in England and Wales from a National Health 
Service (NHS) perspective. Another objective is to esti-
mate the value of information of a randomised controlled 
trial comparing cAVR with the Ross procedure.
MetHOds
Our model structure and inputs were informed by a 
review of published cost-effectiveness models evaluating 
cAVR and other AoV procedures. Detailed methods and 
results are presented in online supplementary material A. 
In brief, we identified 12 papers published between 2012 
and 2016 comparing cAVR, TAVI and medical manage-
ment. As these models did not include the Ross proce-
dure, we adapted their structures to capture important 
features specific to Ross. Input parameters, not identi-
fied in the clinical or economic systematic reviews, were 
informed by targeted literature searches.
Model structure and inputs
Detailed description of the model structure and the 
evidence base for its inputs is provided in online supple-
mentary material B. Briefly, we adopted a discrete-time 
Markov multistate model, a common choice in cost-effec-
tiveness analysis17 and in aortic stenosis.12–14 The model 
structure is illustrated and explained in online supple-
mentary material figures S1 and S2. Patients enter the 
model following an initial Ross or cAVR procedure, and 
their states and events determine costs and QALYs per 
cycle. We adopt an NHS costing perspective and lifetime 
time horizon with a 1-year cycle length, which is consistent 
with previously published models.18–20
We estimated the probabilities of events and transi-
tions using a systematic literature review and meta-anal-
ysis, detailed in online supplementary material C. We 
searched MEDLINE, EMBASE and Cochrane Library 
for studies published between January 1990 and January 
2016 in adults aged 18–65. A Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses flow chart is 
included in online supplementary figures S3. Data from 
41 observational studies and 2 clinical trials were pooled 
using a random-effects meta-analysis model (online 
supplementary figures S4-S12 and table S2).
Several sources were used to estimate the state occu-
pancy and event costs and utilities (online supplementary 
table S1), including evidence from the extensive litera-
ture on stroke prevention in atrial fibrillation.21–24 Costs 
of the cAVR and Ross procedure, and of other one-off 
events, were estimated according to the 2016/2017 NHS 
tariff. Cost estimates were assumed fixed as they repre-
sent agreed prices paid to hospitals for activity. The 
healthy state utility followed that of Doble et al,13 while 
utilities for other states and disutilities for events were 
adapted from the atrial fibrillation literature.24 25 We aver-
aged mechAVR and biological AVR probabilities using an 
estimated 0.23 proportion of cAVR that is biological, with 
further details in online supplementary material B (table 
S2).
Cost-effectiveness outputs
We estimated lifetime costs and QALYs for patients 
undergoing cAVR and Ross procedure, as well as the net 
monetary benefit (NMB) and incremental NMB (INMB). 
The NMB is a summary of both costs and QALYs on the 
monetary scale; it is calculated by subtracting costs from 
monetary benefit, given by multiplying QALYs by a will-
ingness-to-pay threshold, commonly assumed to be £20 
000 for the UK NHS,26 but often up to $100 000 in the 
USA.27 We performed probabilistic sensitivity analysis 
(PSA) to simulate 10 000 lifetime costs, QALYs, NMBs 
and INMBs. Means and 95% Bayesian credible intervals 
(CrI) were estimated for all quantities.11 We generated a 
cost-effectiveness acceptability curve (CEAC), which plots 
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Table 1 Comparison of outcomes between the Ross operation, mechAVR and biological AVR: results from the meta-analysis
Cohorts Ross mechAVR biological AVR
P 
value
Early mortality (%) 46 0.24 (0.17 to 0.34) 0.3 (0.19 to 0.45) 0.28 (0.16 to 0.48) 0.75
Total mortality (%/year) 47 0.54 (0.45 to 0.64) 1.38 (1.11 to 1.74) 2.54 (1.8 to 3.59) <0.001
AoV reoperation (%/year) 47 0.54 (0.42 to 0.69) 0.37 (0.27 to 0.5) 1.28 (0.88 to 1.85) <0.001
Bleeding (%/year) 44 0.11 (0.06 to 0.20) 0.69 (0.5 to 0.96) 0.31 (0.14 to 0.69) <0.001
Thromboembolic events (%/year) 44 0.26 (0.19 to 0.37) 0.86 (0.62 to 1.18) 0.57 (0.39 to 0.84) <0.001
AoV reoperations for IE (%/year) 44 0.16 (0.12 to 0.2) 0.17 (0.1 to 0.27) 0.26 (0.18 to 0.39) 0.08
Conservatively treated IE (%/year) 46 0.21 (0.15 to 0.3) 0.27 (0.18 to 0.42) 0.29 (0.1 to 0.87) 0.64
Total IE (%/year) 39 0.34 (0.27 to 0.42) 0.44 (0.3 to 0.64) 0.63 (0.32 to 1.22) 0.14
RVOT reinterventions (%/year) 22 0.43 (0.34 to 0.54)
Data are from random-effects models. Values in brackets are 95% CI.
AoV, aortic valve; IE, infective endocarditis;RVOT, right ventricular outflow tract; biological AVR, tissue aortic valve replacement; mechAVR, 
mechanical aortic valve replacement.
the probability of Ross procedure or cAVR being most 
cost-effective for a range of willingness-to-pay thresh-
olds.26
Value of information analysis
We estimated the per-person expected value of perfect 
information (EVPI), which is the expected improvement 
in decision making, or value, from removing all uncer-
tainty in all parameters.11 We used multilevel Monte Carlo 
to estimate per-person expected value of partial perfect 
information (EVPPI), the expected value of removing all 
uncertainty in only a subset of parameters.28 We focused 
on sets of parameters likely to be informed by studies 
comparing cAVR with the Ross procedure. We scaled to 
per-population EVPI and EVPPI using a 3.5% per annum 
discounted 25-year technology horizon population size of 
16 376 (details in online supplementary material B).
deterministic sensitivity analyses
We conducted a one-way sensitivity analysis comparing 
Ross procedure with cohorts treated solely with either 
biological AVR or mechAVR, rather than the mixture 
of our base case. Also, as some costs and utility param-
eters were fixed, these would not be included in our 
primary sensitivity analyses of PSA and EVPI. These 15 
parameters are listed in online supplementary material 
B. We conducted one-way sensitivity analyses where these 
parameters were set to 50% and 150% of their values.
Results
epidemiological meta-analysis results
Estimated probabilities are summarised in table 1, 
with forest plots detailed in online supplementary 
material figures S4-S12. Mortality over the follow-up 
period was lower in Ross patients when compared with 
mechAVR and biological AVR (0.54%/year vs 1.38%/
year and 2.54%/year, respectively; p<0.001). There was 
no evidence of difference in early mortality between 
groups. The Ross procedure was associated with lower 
bleeding rates compared with mechAVR and biological 
AVR (0.11%/year vs 0.69%/year and 0.31%/year, respec-
tively; p<0.001). The number of thromboembolic events 
was also lower following the Ross procedure in compar-
ison with mechAVR and biological AVR (0.26%/year 
vs 0.86%/year and 0.57%/year, respectively; p<0.001). 
Reoperation rates on the AoV were reduced in Ross 
patients when compared with biological AVR, but slightly 
higher when compared with mechAVR (0.54%/year vs 
1.28%/year and 0.37%/year, respectively; p<0.001). No 
significant differences were found in terms of infective 
endocarditis.
Cost-effectiveness results
Estimated means and 95% CrI from the cost-effectiveness 
analysis are summarised in table 2. The expected lifetime 
incremental net benefit of £60 952 (£30 236 to £79 464) 
and its narrow CrI which excludes zero suggest there is 
strong evidence that the Ross procedure is more cost-ef-
fective than cAVR at a willingness-to-pay threshold of £20 
000. These findings were repeated at a willingness-to-pay 
threshold of £50 000. There is also strong evidence that 
the Ross procedure is associated with higher lifetime 
QALYs, having an incremental QALY of 3.66 (1.81 to 
4.76), and thus superior effectiveness to cAVR. Although 
the Ross procedure has higher lifetime costs than cAVR, 
with incremental costs of £12 323 (£6108 to £15 972), this 
is outweighed by the larger benefit in QALYs.
The limited uncertainty in our decision is illustrated by 
the CEAC (figure 1), where it appears that beyond a very 
low willingness-to-pay threshold (approximately £3000), 
there is almost 100% probability that the Ross procedure 
is the most cost-effective treatment option. The Ross 
procedure would be most cost-effective for all willing-
ness-to-pay thresholds above £3000 per QALY, including 
£20 000, £50 000 and £100 000.
The deterministic sensitivity analyses showed no impact 
on the results or conclusions of varying the 15 param-
eters. The Ross procedure remained cost-effective at a 
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Table 2 Comparison of cost-effectiveness between the Ross operation and cAVR
cAVR Ross
Incremental 
values
Ross vs AVR
Costs £33 812
(£31 028 to £39 845)
£46 135
(£44 267 to £48 263)
£12 323
(£6108 to £15 972)
QALYs 11.5
(10.4 to 13.3)
15.2
(14.4 to 15.9)
3.66
(1.81 to 4.76)
NMB at £20 000 £196 385
(£177 231 to £227 366)
£257 337
(£241 933 to £270 844)
£60 952
(£30 236 to £79 464)
NMB at £50 000 £541 679
(£490 382 to £627 964)
£712 545
(£672 962 to £748 287)
£170 866
(£84 507 to £222 263)
Values represent means and CI in brackets.
cAVR, conventional aortic valve replacement;NMB, net monetary benefit; QALYs, quality-adjusted life year.
Figure 1 Cost-effectiveness acceptability curve.
willingness-to-pay threshold below £6000 for all sensi-
tivities. Sensitivity analysis found the Ross procedure to 
be superior to biological AVR and mechAVR alone; this 
sensitivity also indicated that mechAVR was superior on 
costs and QALYs to biological AVR, in line with existing 
literature.29
Value of information results
The estimated per-person expected value of information 
(EVPI) at willingness-to-pay £20 000 was £123.70 and 
25-year population EVPI of £2.03 million. This suggests 
that the proposed trial design costing up to £2.03 million 
could be cost-effective. The EVPPI results suggest that 
although studies on the utilities, poststroke disability 
costs and events informed by the meta-analysis could 
offer value of up to £425 000, £342 000 and £307 000, a 
value of up to £1.90 million could come from studying 
only the early event rates of stroke and bleed immediately 
following cAVR or Ross procedure. A trial comparing 
Ross and cAVR and informing the meta-analysis, early 
events and other epidemiological parameters, but not 
costs or utilities, could approach the maximum value of 
£2.03 million for decision making. Value of information 
results are detailed in table 3.
dIsCussIOn
The results of our meta-analysis show lower mortality 
and fewer thromboembolic events for the Ross proce-
dure versus cAVR. Rates of surgical reoperations on the 
AoV were lower than for biological AVR but higher than 
in mechAVR. Our cost-effectiveness analysis found that 
the Ross procedure would be the most cost-effective 
option for all willingness-to-pay thresholds above £3000 
per QALY, due to the greater incremental effectiveness, 
despite the higher lifetime estimated costs.
We also conducted value of information analyses: a trial 
looking only at epidemiological parameters and costing 
up to £2.03 million could offer value for money. Our 
results indicated that most of the important uncertainty 
lies in the expected numbers of bleeds and strokes imme-
diately following cAVR or Ross surgery; a trial estimating 
only these rates could be worth up to £1.90 million to 
decision makers. Limited value of £300 000–£425 000 was 
found for smaller study designs that measured utilities, 
poststroke disability cost or general event rates.
Our meta-analysis is in line with other recent findings, 
namely by Mazine et al30 and McClure et al.31 Both found 
that the Ross procedure had generally better outcomes 
compared with biological AVR or mechAVR. McClure 
et al31 found lower thromboembolic events and better 
health-related quality of life for the Ross procedure, but 
neither meta-analysis considered cost-effectiveness gener-
ally or the value of further research.
As we rely on UK NHS costs, our cost-effectiveness and 
value of information results are specific to that perspec-
tive. However, the results of our meta-analysis and our 
modelling results of 15.2 (14.4 to 15.9) QALYs on the 
Ross procedure compared with 11.5 (10.4 to 13.3) QALYs 
on cAVR are potentially generalisable. To adapt to other 
countries, costs of events and management would need 
to be changed. However, when developing our model 
structure, we referred to models developed in the USA, 
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Table 3 EVPI and EVPPI for input parameters to the cost-effectiveness model
Parameters Individual EVPPI Population EVPPI*
Total EVPI 123.7 (118, 129.4) 2 026 008 (1 932 365; 2 119 651)
Meta-analysis 18.75 (3.887, 33.62) 307 068 (63 655; 550 481)
Utilities 25.97 (11.11, 40.83) 425 290 (181 877; 668 702)
Poststroke disability costs 20.94 (6.078, 35.81) 342 953 (99 541; 586 366)
Bleed or stroke following cAVR or Ross† 116.1 (101.2, 130.9) 1 900 959 (1 657 546; 2 144 372)
Other epidemiological parameters‡ 31.15 (16.28, 46.01) 510 077 (266 665; 753 490)
Ross trial (no costs or utilities)§ 123.7 (108.9, 138.6) 2 026 008 (1 782 596; 2 269 421)
*Population EVPPI given by multiplying individual EVPPI by 8263 population size.
†Early events of stroke or bleed following any of biological AVR, mechAVR or Ross procedure.
‡Other epidemiological parameters are probabilities of disability following stroke; stroke following reoperations for IE on AoV, reoperations for 
any cause on AoV, reoperations on the pulmonary valve; death following stroke, bleeding events, conservatively treated IE, reoperations for 
IE on AoV, reoperations for any cause on AoV, reinterventions on the pulmonary valve.
§Ross trial informing all parameters of the meta-analysis, bleed or stroke immediately following cAVR or Ross procedure, and other 
epidemiological parameters but not costs and utilities.
AoV, aortic valve; EVPI, expected value of perfect information; EVPPI, expected value of partial perfect information; IE, infective endocarditis; 
biological AVR, tissue aortic valve replacement; cAVR, conventional aortic valve replacement; mechAVR, mechanical aortic valve 
replacement.
Canada and Belgium,13 18 32 meaning it is not specific to 
the UK NHS. We would be willing to share our structure 
and software code with interested researchers to develop 
country-specific adaptations.
These results come at a time when the Ross operation is 
under much scrutiny, with several new studies reporting 
excellent long-term outcomes with this technique, 
achieving survival comparable with that of the general 
population.6 7 Several authors have suggested that the 
current guidelines regarding AVR in the young should be 
reconsidered with these new data in mind.33 34
On the other hand, tissue valves are associated with poor 
results in the young, as shown in our meta-analysis, while 
mechanical valves bring the challenge of anticoagulation. 
Young patients, especially women planning a pregnancy, 
are reluctant to accept it, as it negatively impacts quality 
of life.35 In addition, there is a cumulative risk of bleeding 
and thromboembolic events, shown to be significantly 
lower for Ross patients when compared with mechAVR.10 
In our meta-analysis bleeding or thromboembolic events 
were four times more frequent after mechAVR, no doubt 
due to anticoagulation, with a non-negligible cumulative 
1.55% rate per year. In younger, more active patients, the 
promise of fewer restrictions and lower risk of disability 
might overshadow the need for more reinterventions.
Given the more complex nature of the procedure, 
with more reinterventions being performed, there is 
the issue of the total burden on the health system, and 
whether the Ross procedure offers a sufficient advantage 
in quality of life to compensate for the added costs. Our 
economic analysis has shown that, although it has higher 
initial costs, the Ross procedure achieves a significant net 
benefit in the long term, no doubt through the signifi-
cantly lower incidence of stroke.
At present, for the young patients with AoV disease, the 
European guidelines do not mention the Ross procedure 
at all, while the American ones offer it as an alternative 
when anticoagulation is difficult to achieve.36 The accu-
mulated evidence in the past few years strongly suggests 
that the benefits from the Ross procedures outweigh 
the disadvantages in this group. Our study enforces this 
notion and adds the cost-effectiveness dimension. A clin-
ical trial already exists comparing the Ross procedure 
with aortic homograft,8 but currently the main ques-
tion is how it fares when tested against mechAVR and 
new-generation bioprostheses. A clinical trial to answer 
that question is warranted, with sufficient data coming 
from registries to support it; we have shown that even at 
a budget of over £1 million, it would still prove value for 
money to the health service providers.
limitations
To design a computationally practical model, we did 
not include every adverse event associated with AVR. 
We excluded renal failure, pacemaker, arrhythmia and 
myocardial infarction, which were included in previous 
models,12–15 although these are less relevant in non-el-
derly patients. Our model recorded only history of the 
most serious event. These limitations could be overcome 
by expanding the number of model states, as in atrial 
fibrillation models,24 or by including tunnel states,26 but 
this could render EVPPI analysis computationally infea-
sible.37 Adopting an NHS rather than a societal perspec-
tive limits our model’s utility. As the Ross procedure is 
associated with a lower stroke and reoperation rate than 
biological AVR, including societal costs would likely 
increase its cost-effectiveness. Although there was limited 
uncertainty in our results, there were few high-quality 
studies available on many epidemiological parameters 
and utilities, which we represented with wide uncertainty 
margins. Further limitations arise from the meta-anal-
ysis used to inform the parameters and utilities of the 
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economic model. This was primarily based on obser-
vational studies, most of them retrospective. Selection 
criteria were used, and unpublished data, abstracts and 
presentations were excluded, generating a selection bias. 
There is also an inherent bias in the centres used for 
such studies, as the requirement for expertise in the Ross 
procedure limits the choice of centres. Finally, we have 
not estimated the expected value of sample information 
(EVSI). EVPI and EVPPI provide only an upper bound 
on trial value, while EVSI values specific trial designs.37 38 
There is also substantial uncertainty about the number 
of Ross-eligible patients per year; our estimate of 960 
patients per year in the UK was based on extrapolations 
from the existing evidence, although we were conserva-
tive in our estimates.
COnClusIOns
In young patients needing AVR, the Ross operation 
achieves better long-term survival, fewer bleeding and 
thromboembolic events, at the cost of more reinterven-
tions, including those on the right ventricular outflow 
tract. Furthermore, our economic analysis showed that 
the Ross procedure is more cost-effective compared with 
cAVR. Despite this, the Ross operation does not have a 
clear place in guidelines, in lack of a good-quality clinical 
trial. Our study found that a trial comparing these options 
costing up to £2 million could offer value for money. 
An international collaboration started to generate this 
evidence prospectively and the trial is now in the pilot 
phase.
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